New hope for lung cancer: smart combo targets hidden risk after immunotherapy

NCT ID NCT06951646

Recruiting now Disease control Sponsor: Second Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a new drug (ivonescimab) to standard chemotherapy can help people with advanced non-small cell lung cancer who did well on initial immunotherapy but still have signs of cancer DNA in their blood. About 70 adults aged 18-75 will be randomly assigned to get the new combo or standard care. The goal is to see if this approach delays cancer progression and improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE CHECKPOINT INHIBITORS (ICIS) NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Army Medical Center (Daping Hospital)
NOT_YET_RECRUITING

Chongqing, China
Changsha Central Hospital
NOT_YET_RECRUITING

Changsha, China
Faculty of Medicine, The Chinese University of Hong Kong
NOT_YET_RECRUITING

Hong Kong, China
Guiyang Public Health Clinical Center
NOT_YET_RECRUITING

Guiyang, China
Hubei Cancer Hospital
NOT_YET_RECRUITING

Wuhan, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, 410011, China
Kiang Wu Hospital, Macao
NOT_YET_RECRUITING

Macao, China
Liaoning Cancer Hospital and Institute
NOT_YET_RECRUITING

Shenyang, China
Renmin Hospital of Wuhan University
NOT_YET_RECRUITING

Wuhan, China
Shanxi Bethune Hospital
NOT_YET_RECRUITING

Taiyuan, China
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITING

Nanning, China
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITING

Nanchang, China
The First Affiliated Hospital of Xinxiang Medical University
NOT_YET_RECRUITING

Xinxiang, China
The First Hospital of Changsha
NOT_YET_RECRUITING

Changsha, China
The Second Xiangya Hospital of Central South University
RECRUITING

Changsha, 410011, China
The Third Hospital of Changsha
NOT_YET_RECRUITING

Changsha, 410011, China
The Third Xiangya Hospital of Central South University
NOT_YET_RECRUITING

Changsha, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITING

Wuhan, China
Xiangya Hospital of Central South University
NOT_YET_RECRUITING

Changsha, 410011, China
Zhuzhou Central Hospital
NOT_YET_RECRUITING

Zhuzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.